Fresenius sells biotech unit to Neopharm owners; EMA approves Remicade copycats; Bayer's Stivarga also gets nod;

@FiercePharma: Finally… EMA's press release about this week's drug moves: Release | Follow @FiercePharma

@EricPFierce: There is a connection between the separate deals Aspen has announced with MSD and GSK. It is heparin. More | Follow @EricPFierce

@CarlyHFierce: There are billions of dollars to be saved on healthcare spending via adherence... but how? Story | Follow @CarlyHFierce

> German drugmaker Fresenius has sold its Fresenius Biotech unit to the Fuhrer family, owners of Isreal's Neopharm, for an undisclosed price. Release

> The EMA today recommended approval of two biosimilars which will face off against Remicade, the blockbuster arthritis drug from Johnson & Johnson ($JNJ) and Merck ($MRK). Report

> Experts at the European Medicines Agency have recommended approval of Bayer's drug Stivarga for the treatment of metastatic colorectal cancer. Story

> Sanofi ($SNY) said that regulators in Japan have approved its Type 2 diabetes drug Lyxumia (lixisenatide) . Release

Medical Device News

@FierceMedDev: Boston Scientific buying Bard's electrophysiology biz for $275M. News | Follow @FierceMedDev

@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from DIA 2013: Feature | Follow @DamianFierce

@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Story | Follow @MichaelGFierce

> Despite deaths, docs and patients sticking with Medtronic pump. Item

> Roche Diagnostics scores another FDA victory. Story

> Philips inks $300M deal for service and R&D. News

> Industry: Tightening EU device regs will strangle business. Article

Biotech News

@FierceBiotech: ICYMI yesterday: J&J's pharma chairman lands 'more deals' in Boston innovation push. News | Follow @FierceBiotech

 @JohnCFierce: Where are the FDA approvals on biosims? EMA backs two Remicade knockoffs. Release | Follow @JohnCFierce

@RyanMFierce: Big week for Prosensa. Priced $78M IPO on the heels of breakthrough status for lead DMD Rx partnered w/ GSK. PR | More | Follow @RyanMFierce

> Lab animal wars: Scientists blast living conditions of stolen mouse models. Story

> Buyout buzz: Royalty might mount joint effort to acquire Elan. Article

> Resverlogix stock craters on failure of cardio drug trial. Report

And Finally... Regulators in the U.K. and for the World Health Organization (WHO) have both said that audits of Ranbaxy Laboratories have found no issues with the drugs it currently is producing. Story

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.